Compare Neurocrine Biosciences Inc (NBIX) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Palo Alto Networks Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Palo Alto Networks Inc trades at $341.25 (market cap $284.16B). The key difference: Palo Alto Networks Inc is far larger — about 16.3× Neurocrine Biosciences Inc's market cap. Which is the better fit depends on your goals.
| NBIX | PANW | |
|---|---|---|
Market Cap | $17.40B | $284.16B |
Sector | Health | Technology |
52-Week High | $180.55 | $358.68 |
52-Week Low | $123.10 | $141.67 |
Enterprise Value | $16.49B | $283.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Palo Alto Networks (PANW) trades at $342.15, down 4.61% today, yet maintains a bullish technical trend with strong analyst support. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.85 surpassing the $0.793 estimate. The company shows robust revenue growth, reaching $9.22B in 2025, and positive cash flow trends, though valuation ratios like a P/E of 303.18 remain elevated. News highlights focus on AI-driven cybersecurity demand and strategic acquisitions, such as the intent to enhance its observability platform announced on July 21, 2026.
Outlook is positive due to strong market positioning in cybersecurity and AI integration, but high valuations and competitive pressures pose risks. Investment opportunity lies in sustained earnings growth and sector tailwinds, while investors should monitor execution on guidance and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
